证券代码：300119 证券简称：瑞普生物 公告编号：2023-022 天津瑞普生物技术股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）《2022年年度报告》 全文及摘要以及其他相关文件已于2023年4月1日刊登在中国证券监督管理委员 会指定的创业板信息披露网站。 特此公告。 天津瑞普生物技术股份有限公司 董事会 二〇二三年四月一日 1 为便于广大投资者进一步了解公司2022年年度报告及经营情况，公司拟定于 2023年4月14日（星期五）下午15:00-17:00在"价值在线（www.ir-online.cn）" 举行2022年度业绩说明会。本次年度业绩说明会将采用网络远程的方式举行，投 资者可登录"价值在线（www.ir-online.cn）"参与本次说明会。 公司董事长李守军先生，独立董事周睿女士，财务负责人李改变女士，保 荐代表人郭玉良女士，董事会秘书谢刚先生将出席本次说明会。 为充分尊重投资者，提升本次交流的针对性，现就公司2022年度业绩说明 会提 ...

Group 1: Industry Challenges - The poultry market has faced unprecedented difficulties due to H7N9 avian flu and food safety incidents, leading to a prolonged downturn in chicken consumption [2] - The pig farming sector experienced continuous losses throughout the year, with significant losses at the beginning of the year [3] - The animal health industry has seen a slow recovery in market conditions, resulting in a decline in company performance [3] Group 2: Organizational Adjustments - The company is implementing a "research-production-sales integration" strategy, establishing various development centers to respond to market changes and enhance industry development [3] - A new group control model focusing on "industry development centers," "profit centers," and "responsibility centers" is being adopted to improve organizational efficiency and core competitiveness [3] Group 3: Product Development - The company is developing a range of new livestock products, including vaccines for porcine infectious gastroenteritis and porcine epidemic diarrhea [3] - The animal vaccine expansion project is currently underway, with plans to launch several new products in 2015 [3]

证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 编号：15 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 安信证券 郑颖欣、博时基金 葛晨、中银基金 王帅、华夏基 | | | | | | 人员姓名 | | 金 李恒、招商证券 周莎、国投瑞银 孙文龙、鹏山资产 杨明 | | | 石岩。 | 韬、平安资管 黄文峰、浙银金阁 朱学根、和君咨询 乔圣泽 | | 时间 | 2016 年 9 月 22 | 日 10:30-12:00 | | 地点 | 公司九楼会议室 | | | 上市公司接待人 | | 董事长、总经理 李守军 副 ...

Group 1: Company Development and Strategy - The company has transformed from a product seller to a comprehensive service provider, learning from leading global animal health companies [1] - In Q1 2020, the company achieved rapid growth due to strategic planning over the past few years [1] - The company has made significant progress in internal management efficiency and product development, focusing on future-oriented planning [3] Group 2: Vaccine Development and Market Position - The company emphasizes dual improvements in technical and product standards for poultry vaccines, achieving a replacement of imported products with stable quality [3] - Plans to establish a research center for avian influenza vaccines in Southern China, enhancing production capacity and targeting ASEAN markets [3] - The poultry business is well-structured and maintains high-speed, healthy growth [3] Group 3: Innovations in Livestock Products - The company has innovated marketing models in livestock vaccines, focusing on customer-centric approaches and service provision [3] - A mature mechanism for product sales has been established, with plans for large-scale promotion [3] - Internal departments are aligned under a customer-centric principle, contributing to overall value [3] Group 4: Core Competitiveness in Animal Health Industry - Short-term competitiveness relies on marketing capabilities, while mid-term focus is on management and production stability, and long-term on R&D capabilities [3] Group 5: Pet Products Sector - The pet products sector is a strategic focus, with rapid growth in pet pharmaceuticals and vaccines [4] - The company plans to deepen collaboration with its affiliate, Ruipai Pet Hospital, to enhance product promotion [4] Group 6: Future Trends in Animal Health Industry - The animal health industry is expected to accelerate consolidation towards larger and leading companies, providing greater development space for industry leaders [4]

Group 1: Industry Changes and Impact - The African swine fever epidemic has significantly impacted China's livestock industry, leading to a severe reduction in pig farming capacity and increased demand for chicken meat as a substitute [4]. - The market for poultry vaccines has expanded following the upgrade of avian influenza vaccine products at the end of last year, indicating a growing trend towards reduced antibiotic use in the livestock sector [4]. Group 2: Poultry Industry Development - The poultry farming industry is experiencing standardization in the broiler sector and scaling in the egg-laying sector, with the broiler industry showing a higher degree of scalability [4]. - The African swine fever epidemic may affect consumer meat product consumption, with white feather broilers likely to fill the gap in consumption structure, driving rapid development in the poultry farming industry [4]. Group 3: Company Progress in Avian Influenza Vaccine Market - The company’s subsidiary, Guangzhou South China Agricultural University Biological Pharmaceutical Co., Ltd., has received approval for a trivalent inactivated vaccine, which will fully participate in market bidding this year [5]. - The company plans to leverage its long-term quality resources to enhance marketing efforts for avian influenza vaccines and reduce production costs through the use of suspension culture technology [5]. Group 4: Future Development Directions - The successful approval of the trivalent inactivated vaccine (H5+H7) will be a key product for the company over the next three years, with the poultry farming industry's ongoing prosperity expected to drive both volume and price increases for poultry vaccines [5]. - The company aims to expand into the pet vaccine and pet medicine sectors, anticipating significant growth opportunities in these areas over the next 20 years [5].

Group 1: Company Overview - The company introduced its 2020 performance highlights and operational achievements, along with plans for a non-public offering and strategic direction [1] - The focus was on expanding distribution channels and increasing coverage in key domestic breeding counties [4] Group 2: Product and Quality Management - The company established a quality management center and centralized procurement department to oversee quality and material procurement across subsidiaries [4] - A revised quality philosophy and objectives were implemented, with product line management aimed at improving product quality based on customer needs [4] Group 3: Strategic Transformation and Organizational Incentives - The company initiated comprehensive management changes starting with strategic transformation [4] - Organizational restructuring was undertaken to enhance the marketing system and allocate resources towards strategic business areas [4] - An incentive mechanism was established to promote performance and encourage young talent, including job rotation and performance-based elimination [4] Group 4: Pet Hospital Development - The company plans to expand cooperation with Ruipai Pet Hospital and broaden the pet distributor network [4] - Focus on core and specialty products in the pet business segment to provide integrated solutions for customers [4] - Accelerating digital transformation and e-commerce capabilities in the pet sector [4]

编号：2021-002 1 证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------------------------------------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他：电话交流会 | | | 参与单位名称及 | 西南证券：徐卿，刘佳宜 | | | 人员姓名 | 淡水泉：俞仁钦 | | | | 银叶投资：刁凯峰 | | | | 中庚基金：张炜舜 | | | | | | | | | | | | 工银瑞信：王鹏 大成基金：齐炜中 中国农业产业基金：万毅 长安基金：朱施乐 | | | 时间 | 2021 ...

证券代码：300119 证券简称：瑞普生物 编号：2022-001 天津瑞普生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | □特定对象调研 □媒体采访 □业绩说明会 □新闻发布会 现场参观 其他（电话会议） | 分析师会议 □路演活动 | | 参与单位名称及 ...

Group 1: Company Performance Overview - The company reported a total revenue of 90,833.74 million yuan in the first half of the year, a year-on-year decrease of 12.72% [2] - In Q2, the revenue was 51,753.08 million yuan, showing a quarter-on-quarter growth of 32.43% [2] - The net profit for the first half was 15,358.81 million yuan, down 31.58% year-on-year, with a net profit attributable to shareholders of 13,983.26 million yuan, also down 31.32% [2] Group 2: Product Development and Market Strategy - The company launched several new products in the animal health sector, including vaccines for poultry and swine, and various pet products [3][4] - The newly launched product Mopuxin (a broad-spectrum antiparasitic) has achieved over 10 million yuan in revenue since its release [4] - The company aims to enhance its product matrix in the pet sector, collaborating with strategic partners to strengthen its market presence [5] Group 3: Market Position and Competitive Landscape - The company has developed over 90% of the top 100 domestic pig farming groups, indicating strong market penetration [4] - The high pathogenic avian influenza vaccine generated revenue of 123 million yuan in the first half, down 13.94% year-on-year [6] - The company is focusing on maintaining a competitive edge through cost control and product innovation amidst increasing market competition [7] Group 4: Future Outlook and Strategic Initiatives - The company plans to continue investing heavily in R&D to enhance its core technological capabilities and improve production efficiency [3] - It aims to expand its international presence and become a leading player in the animal health industry [3][5] - The company is also focusing on building a robust ecosystem in the pet industry through strategic partnerships and digital integration [5]

编号：2022-004 证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...